Physician profile
Daniel Peralta
NPI 1952990079
$3,097.03
in general payments reported to CMS, 2019-2025
28 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.90 · 2023: $309 · 2024: $1,344 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,040.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $563.70 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $459.71 | 2024-2025 | |
| Pfizer INC. | $330.49 | 2023-2025 | |
| Lilly USA, LLC | $287.30 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $206.58 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $191.47 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.34 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $124.78 | 2024-2025 | Veozah |
| Sanofi Pasteur INC. | $95.24 | 2024-2025 | |
| Glaxosmithkline, LLC. | $86.43 | 2024-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $68.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Organon LLC | $56.90 | 2022 | |
| Viatris Specialty LLC | $55.55 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $55.36 | 2025 | |
| Phathom Pharmaceuticals, INC. | $50.06 | 2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $48.22 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.12 | 2024-2025 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $37.76 | 2024-2025 | Gvoke Hypopen |
| Exeltis, USA INC. | $30.20 | 2025 | Slynd |
| Vertex Pharmaceuticals Incorporated | $27.64 | 2024 | |
| Novartis Pharmaceuticals Corporation | $27.08 | 2025 | |
| Inspire Medical Systems, INC. | $24.25 | 2025 | Inspire |
| Seqirus USA INC | $17.56 | 2025 | Fluad, Flucelvax |
| Coopersurgical, INC. | $17.09 | 2025 | Paragard T 380a |
| Amgen INC. | $16.24 | 2024 | Repatha |
| Angiodynamics, INC. | $13.94 | 2024 | Auryon Laser System 100-120 Vac |
| Merck Sharp & Dohme LLC | $13.78 | 2023 | Gardasil 9, Rotateq, M-M-R II |
| Mylan Specialty L.P. | $13.48 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Peralta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.